🎉 M&A multiples are live!
Check it out!

Theravance Valuation Multiples

Discover revenue and EBITDA valuation multiples for Theravance and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Theravance Overview

About Theravance

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).


Founded

2013

HQ

United States of America
Employees

97

Website

theravance.com

Financials

LTM Revenue $75.6M

LTM EBITDA n/a

EV

$398M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Theravance Financials

Theravance has a last 12-month revenue of $75.6M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Theravance achieved revenue of $64.4M and an EBITDA of -$38.5M.

Theravance expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Theravance valuation multiples based on analyst estimates

Theravance P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $57.4M $64.4M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$42.7M -$38.5M XXX XXX XXX
EBITDA Margin -74% -60% XXX XXX XXX
Net Profit $872M -$55.2M XXX XXX XXX
Net Margin 1519% -86% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Theravance Stock Performance

As of April 15, 2025, Theravance's stock price is $9.

Theravance has current market cap of $437M, and EV of $398M.

See Theravance trading valuation data

Theravance Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$398M $437M XXX XXX XXX XXX $-0.87

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Theravance Valuation Multiples

As of April 15, 2025, Theravance has market cap of $437M and EV of $398M.

Theravance's trades at 5.3x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Theravance's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Theravance and 10K+ public comps

Theravance Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $398M XXX XXX XXX
EV/Revenue 6.2x XXX XXX XXX
EV/EBITDA -10.3x XXX XXX XXX
P/E -7.7x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -33.5x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Theravance Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Theravance Valuation Multiples

Theravance's NTM/LTM revenue growth is 30%

Theravance's revenue per employee for the last fiscal year averaged $0.7M, while opex per employee averaged $1.1M for the same period.

Over next 12 months, Theravance's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Theravance's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Theravance and other 10K+ public comps

Theravance Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 12% XXX XXX XXX XXX
EBITDA Margin -60% XXX XXX XXX XXX
EBITDA Growth -10% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -29% XXX XXX XXX XXX
Revenue per Employee $0.7M XXX XXX XXX XXX
Opex per Employee $1.1M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 58% XXX XXX XXX XXX
Opex to Revenue 166% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Theravance Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Small Molecules comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Theravance M&A and Investment Activity

Theravance acquired  XXX companies to date.

Last acquisition by Theravance was  XXXXXXXX, XXXXX XXXXX XXXXXX . Theravance acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Theravance

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Theravance

When was Theravance founded? Theravance was founded in 2013.
Where is Theravance headquartered? Theravance is headquartered in United States of America.
How many employees does Theravance have? As of today, Theravance has 97 employees.
Who is the CEO of Theravance? Theravance's CEO is Mr. Rick E. Winningham.
Is Theravance publicy listed? Yes, Theravance is a public company listed on NAS.
What is the stock symbol of Theravance? Theravance trades under TBPH ticker.
When did Theravance go public? Theravance went public in 2014.
Who are competitors of Theravance? Similar companies to Theravance include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Theravance? Theravance's current market cap is $437M
What is the current revenue of Theravance? Theravance's last 12-month revenue is $75.6M.
What is the current EV/Revenue multiple of Theravance? Current revenue multiple of Theravance is 5.3x.
What is the current revenue growth of Theravance? Theravance revenue growth between 2023 and 2024 was 12%.
Is Theravance profitable? Yes, Theravance is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.